Carbon Biosciences’ Post

🚀 Meet Radar Therapeutics: an innovative leader in genetic medicine and winner of the WACKER Biotech Discovery Award! Its platform for selectively activated mRNAs can precisely control the expression and activity of genetic medicines at the cell type or even cell state level, thereby revolutionizing treatment for a broad array of autoimmune, oncological, and rare diseases. Co-founded by Sophia Lugo, MS, MBA and Dr. Eerik Kaseniit, PhD, Radar Therapeutics emerged from Stanford University and MIT as a pioneering venture that addresses the limitations in current cell and gene therapies—high costs, scalability challenges, and safety risks. As the Wacker Biotech Discovery Awardee, Radar will receive in-kind credits to work with the experienced team at Wacker to develop its advanced therapeutics and advance its mission of accessible genetic medicine for all. Reflecting on her journey, Sophia shared, "I have always been passionate about equitable access to healthcare and innovation. We should innovate with all patients of all backgrounds in mind. I committed my career to solving critical problems and was fortunate to meet Dr. Eerik Kaseniit, a brilliant bioengineer who invented the foundational technology behind RADAR while at Stanford." With backing from leading VCs and pharma, Radar is on a mission to revolutionize programmable medicines. Come meet them at the CLS Innovation Showcase on Dec 10. 🔗 For more information about the contract development and manufacturing services of Wacker Biotech, please visit https://bit.ly/3AAiKRU and to learn more about Radar Therapeutics and their impact visit https://bit.ly/48vBfDG. #GeneTherapy #LifeSciences #HealthcareInnovation #SyntheticBiology #EquitableHealthcare #CALifeSciences

With Advanced Therapies Week 2025 just around the corner, we’re thrilled to spotlight Dallas, Texas—a burgeoning biotech hub. Home to Biotech+ Hub at Pegasus Park's accelerator programs and numerous pioneering cell and gene therapy companies, Texas is leading the charge in life sciences innovation. 🧬✨ Curious about the key players to watch? Explore our list of Texas biotech companies, just minutes from the Kay Bailey Convention Center. View the full article to discover how Texas is shaping the future of biotech. https://lnkd.in/eygu-_u7 #AdvancedTherapiesWeek #BiotechInnovation #ATW25 #AdvancedTherapies

For over a decade, Applied StemCell has been a trusted partner to scientists, expanding what you can accomplish through iPSCs. Our human iPSC lines are consistently generated and rigorously characterized, providing you with robust tools to advance your disease research, drug discovery studies, and cell-based medicine development. We understand that as a researcher, you need reliability and reproducibility. That’s why our iPSC lines are: - Pluripotency-Validated: Ensuring differentiation potential across all three germ layers. - Genetically Stable: Thoroughly tested to maintain integrity across passages. - Customizable: Tailored to meet the specific demands of your experimental design, including disease-relevant mutations and reporter lines. Whether you're modeling complex diseases or optimizing cell therapy approaches, our iPSCs are the high-quality foundation you need to produce. Join your peers who trust Applied StemCell to deliver the tools they need for cutting-edge discoveries.

For over a decade, Applied StemCell has been a trusted partner to scientists, expanding what you can accomplish through iPSCs. Our human iPSC lines are consistently generated and rigorously characterized, providing you with robust tools to advance your disease research, drug discovery studies, and cell-based medicine development. We understand that as a researcher, you need reliability and reproducibility. That’s why our iPSC lines are: - Pluripotency-Validated: Ensuring differentiation potential across all three germ layers. - Genetically Stable: Thoroughly tested to maintain integrity across passages. - Customizable: Tailored to meet the specific demands of your experimental design, including disease-relevant mutations and reporter lines. Whether you're modeling complex diseases or optimizing cell therapy approaches, our iPSCs are the high-quality foundation you need to produce. Join your peers who trust Applied StemCell to deliver the tools they need for cutting-edge discoveries.

🌟 Recap of ISCT, International Society for Cell & Gene Therapy Conference 2024 in Vancouver! 🌟 From May 29-31, I had the incredible opportunity to attend the ISCT Conference in Vancouver. It was a vibrant gathering of over 2500 delegates from around the world, bringing together leading scientists and developers in the cell and gene therapy field. Here are some of the key highlights and takeaways: 🔹 Diverse Tracks and Insights: The conference featured up to 6 tracks covering development, clinical trials, regulatory issues, bioprocessing, manufacturing, and roundtable discussions. This diversity provided a comprehensive overview of the latest trends and challenges in our industry. 🔹 Exhibition Hall: With approximately 110 exhibitors, the exhibition hall was a hub of innovation. It was inspiring to see the latest advancements in technology and services that are driving our field forward. 🔹 Networking and Collaboration: Engaging with professionals like Paul Priebe, an independent consultant, and Alina Oancea from Mayo Clinic Florida, highlighted the importance of collaboration. Discussions ranged from the challenges in CAR-T therapies to the potential of iPSCs, emphasizing the diverse approaches in tackling complex medical challenges. 🔹 Future Outlook: The emphasis on automation and data sharing was a recurring theme. Sessions like "Elevating Cell Therapy Manufacturing Using Industry 4.0" underscored the transition towards more integrated and automated processes, aiming for higher efficiency and reduced costs. 🔹 Innovative Solutions: We saw groundbreaking advancements in aseptic processing technologies and aseptic manufacturing. Harro Höfliger's own contributions in this field were well-received and sparked numerous insightful conversations. 🔹 Looking Ahead: Next year's ISCT Conference will be held from May 7-10 in New Orleans. Mark your calendars! 📅 It was an enriching experience, and I'm looking forward to implementing some of these insights in our work at Harro Höfliger. Let's continue pushing the boundaries of what's possible in cell and gene therapy! 🚀 #ISCT2024 #CellTherapy #GeneTherapy #AsepticProcessing #Innovation #Pharmaceuticals #HarroHöfliger #Automation #DataSharing #CAR_Therapies #iPSCs

Targeted modification of a cell’s DNA 🧬 via genome editing provides a powerful tool for fundamental biological research, early stage drug discovery, and for the development of novel cellular therapeutics, e.g. immunotherapy. The ability of CRISPR to introduce specific modifications into the genome allows tremendous flexibility in the choices of targets and assays and allows a precise determination of the drug target as part of functional genomics. Join Dr. Heyne Cecilia Lee (AbbVie Deutschland GmbH & Co. KG, Neuroscience Discovery) at our free Webinar to learn about: ✅ The role of CRISPR in early drug discovery efforts, e.g. target validation ✅ How to generate Knock-outs in myeloid cells ✅ How to target microglial pathways for Alzheimer’s disease therapy https://lnkd.in/gAJ_SHKg

🔬 Unveiling the Giants: Top Biotech Companies in the USA for 2024! 🇺🇸 As we step into 2024, the biotech landscape in the United States continues to evolve and innovate. Here's a quick look at the frontrunners shaping the future of healthcare and technology: Moderna: Pioneering mRNA therapeutics Regeneron: Revolutionizing antibody treatments Illumina: Leading the charge in genomic sequencing Biogen: Advancing neuroscience and rare diseases Vertex Pharmaceuticals: Transforming cystic fibrosis treatment These companies are not just pushing boundaries; they're redefining what's possible in medicine and biotechnology. From groundbreaking vaccines to cutting-edge gene therapies, the future looks promising! 💉🧬🔬 What biotech innovations are you most excited about? Share your thoughts in the comments below! #Biotech2024 #USBiotechLeaders #HealthcareInnovation #FutureOfMedicine #BiotechTrends

Cell and gene therapies (CGT) represent the future of precision medicine, offering the potential to improve patient outcomes across a range of diseases. However, bringing these complex therapies from bench to bedside presents unique challenges at every stage of development. As the CGT landscape continues to evolve rapidly, developers need an experienced partner who can provide integrated solutions to overcome key hurdles at every stage from early research through commercialization. In a recent presentation for the Korea Biomedicine Industry Association (KoBIA), Maryland Rosenfeld Franklin, PhD, vice president and enterprise head of CGT at Labcorp, shared how Labcorp’s comprehensive CGT capabilities support all aspects of global CGT development, including preclinical pharmacology, companion diagnostics (CDx) development and validation. Please access to the streaming from here: bit.ly/3KqSgns #labcorp #cellandgenetherapy #cdx #kobia

“When we first started working together, nobody was interested in RNA. We couldn't get funding. We couldn't get papers published. But we saw the potential and we saw enormous potential, and as we were doing our work, the data kept supporting an enormous potential.” And thank goodness they did! This week’s #SciencEE features Drew Weissman, MD, PhD, 2023 The Nobel Prize in Medicine! Famously known for his groundbreaking, nobel-prize winning work in #mRNA science, Dr. Weissman joined our recent scientific symposium to discuss the potential of lipid nanoparticles to deliver gene editing therapies to treat #cysticfibrosis. Thank you to our 2024 #CFAwarenessMonth Tier 2 sponsors — Boehringer Ingelheim, Viatris, 4D Molecular Therapeutics, ReCode Therapeutics, Baxter International Inc. and Enterprise Therapeutics — for supporting our #SciencEE series! #CrossOutCF #CFAwarenessMonth #CFAwareness #CysticFibrosis Penn Medicine, University of Pennsylvania Health System

Have you ever received a gene or cell therapy? Did you ever wonder how these therapies are regulated? One of our missions at the #CTGCT is to increase the knowledge of the general public about the research and applications related to gene and cell therapy. This is the first post in a collection where we will explain more about these topics. So today we talk about #ATMPs. Advanced Therapy Medicinal Products (ATMPs) are revolutionizing the field of medicine! These innovative therapies leverage cutting-edge genetic, somatic cell therapy, and tissue engineering to target complex diseases at the genetic, metabolic, or cellular level. From treating conditions like hemophilia and diabetes to addressing central nervous system disorders and cancer, ATMPs offer new hope for unmet medical needs. Given their complexity, ATMPs follow specific regulatory guidelines, established by the European Commission in 2007, ensuring they meet high safety and efficacy standards. As the demand for these breakthrough therapies grows, so does the potential for significant advancements in healthcare. Join us on this exciting journey at the forefront of cellular and molecular biotechnology! You can learn more about ATMPs in this link: #CellAndGeneTherapy #CGT #ATMPs #Biotechnology #HealthcareInnovation #EMA